Valuation: Armata Pharmaceuticals, Inc.

Market Cap 125M 111M 103M 93.93M 177M 11.89B 180M 1.24B 487M 6.21B 470M 460M 19.78B P/E 2026 *
-1.81x
P/E 2027 * -2.33x
Enterprise Value 125M 111M 103M 93.93M 177M 11.89B 180M 1.24B 487M 6.21B 470M 460M 19.78B EV / Sales 2026 *
29.5x
EV / Sales 2027 * 45.6x
Free-Float
32.36%
Yield 2026 *
-
Yield 2027 * -
1 day+9.06%
1 week-7.16%
Current month-8.17%
1 month-17.80%
3 months-25.28%
6 months-70.70%
Current year-46.34%
1 week 2.74
Extreme 2.745
3.84
1 month 2.74
Extreme 2.745
4.56
Current year 2.74
Extreme 2.745
14.98
1 year 2.74
Extreme 2.745
16.34
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 2023-07-10
Director of Finance/CFO 42 2024-08-15
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 2019-05-08
Director/Board Member 66 2020-02-11
Director/Board Member 51 2020-02-11
Date Insider Type Main position Quantity % Market Cap. Importance
7/10/26 Tax

Chief Executive Officer

-14,041 0.0382%
4/24/26 Free

Director

51,280 0.1400%
3/14/26 Tax

Public Communications Manager

1,030 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
+9.06%-7.16%-0.88%+58.22% 125M
-6.60%-8.56%+49.38%+63.51% 65B
-4.09%-0.11%+2.22%+53.15% 51.19B
+0.03%+5.56%+9.10%+69.05% 51.2B
-1.53%+2.70%+30.48%+34.12% 43.93B
-1.34%+4.12%+16.64%+115.13% 41.96B
-5.97%-6.22%+228.95%+454.22% 38.14B
+6.53%+8.02%+16.40%+53.41% 33.24B
-0.90%-10.49%+37.09%-3.70% 25.2B
-2.76%-9.54%-16.58%-9.19% 22.03B
Average -0.76%-3.50%+37.28%+88.79% 37.2B
Weighted average by Cap. -2.29%-1.21%+42.13%+95.49%

Financials

2026 *2027 *
Net sales 4.25M 3.78M 3.5M 3.19M 6.01M 403M 6.11M 42.09M 16.5M 210M 15.95M 15.61M 671M 2.75M 2.44M 2.27M 2.06M 3.89M 261M 3.95M 27.23M 10.68M 136M 10.32M 10.1M 434M
Net income -76.6M -68.09M -63.11M -57.42M -108M -7.27B -110M -759M -297M -3.79B -287M -281M -12.09B -72M -64M -59.32M -53.97M -102M -6.83B -103M -713M -280M -3.57B -270M -264M -11.37B
Net Debt - -
Projected Income Statement - Annual - Armata Pharmaceuticals, Inc.
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
26-10-16 US$3.370 +9.06% 154,319
26-10-15 US$3.090 +11.15% 115,784
26-10-14 US$2.780 -10.32% 125,555
26-10-13 US$3.100 -14.60% 223,201
26-10-12 US$3.630 0.00% 47,204
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Armata Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.370USD
Average target price
17.50USD
Spread / Average Target
+419.29%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Armata Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. ARMP Stock